GSK stock: company announces oncology deal and positive Jideytro data

GSK announced a potential $750 million Chimagen deal for a multiple myeloma T-cell engager. The company also reported positive Jideytro data in first-line lung cancer.

GSK announced on September 15, 2026, that it had entered an agreement to acquire full global rights to a trispecific T-cell engager from Chimagen Biosciences for development in multiple myeloma. The program is expected to enter Phase I trials in 2027, and the agreement has a total potential value of up to $750 million, subject to customary closing conditions, according to GSK.

Jideytro trial data

In a September 14, 2026 release, GSK said Jideytro achieved a 94% objective response rate among 94 evaluable patients in the TKI-naive ARROS-1 cohort, with 90% of patients progression-free at 12 months. GSK said the data support a planned supplemental US regulatory submission in 2026, as reported in its press release.